Patterns of endpoint use in oncology pragmatic clinical trials: A review of randomised studies

Christopher Cronin

doi:10.1016/j.ejca.2026.116958

Patterns of endpoint use in oncology pragmatic clinical trials: A review of randomised studies

2026-07-22

0

PRE

AI

C

Christopher Cronin *

F

F. Borges

M

Murielle E. Mauer

D

Denis Lacombe

B

Bert Dhondt

DOI：10.1016/j.ejca.2026.116958

Original

Original request for help

Save

Abstract

En 中文

• This review identified 53 randomised oncology pragmatic clinical trials (PCTs). • Most were phase III, multicentric, superiority trials of anticancer interventions. • Surrogate endpoints were the most common category of primary endpoint used. • Further work is required to promote patient-centred endpoints in oncology PCTs.

Keywords:

Pragmatic clinical trials

Treatment optimisation

De-escalation

Surrogate endpoints

Patterns of endpoint use in oncology pragmatic clinical trials: A review of randomised studies

Abstract

Journal

Organization